Source: The Indian Express

---

0.1 Change in India’s drug market

0.1.1 Weight loss drugs India became the highest-selling medicines by value in 2025.
0.1.2 This occurred despite very limited patient usage.
0.1.3 Obesity is increasingly treated as a medical disease rather than a lifestyle issue.

0.2 What are GLP-1 weight loss drugs in India

0.2.1 These medicines belong to the GLP-1 receptor agonist class.
0.2.2 They suppress appetite, slow digestion, and regulate blood glucose.
0.2.3 They enable clinically supervised weight loss.

0.3 Entry of modern obesity drugs in India

0.3.1 Tirzepatide (Mounjaro) was launched in March 2025.
0.3.2 Semaglutide (Wegovy) was launched in June 2025.
0.3.3 These launches marked India’s shift to pharmacological obesity treatment.

0.4 Why sales surged despite low usage

0.4.1 Monthly treatment costs run into several thousand rupees.
0.4.2 Most patients pay out of pocket with minimal insurance coverage.
0.4.3 A small affluent urban population drove high sales value.

0.5 Change in patient behaviour

0.5.1 Indian patients earlier avoided long-term spending on obesity treatment.
0.5.2 Rising awareness of diabetes and cardiovascular risks changed attitudes.
0.5.3 Obesity treatment is increasingly viewed as preventive healthcare.
0.5.4 This shift is expanding the market for weight loss drugs India.

0.6 Medical uncertainties still remain

0.6.1 Optimal duration of therapy is not clearly established.
0.6.2 Safe protocols for dose tapering or discontinuation remain unclear.
0.6.3 Weight regain is commonly observed after stopping medication.

0.7 Benefits beyond weight loss

0.7.1 A 2025 study in The Lancet reported reduced cardiovascular events with Semaglutide.
0.7.2 These benefits were observed even among non-diabetic patients.
0.7.3 Cardiovascular protection appears independent of weight loss.

0.8 Why patents matter for pricing

0.8.1 Patents provide exclusive manufacturing and marketing rights.
0.8.2 The core Semaglutide patent expired in September 2024.
0.8.3 The injection-device patent expires in March 2026.

0.9 Role of Indian pharmaceutical companies

0.9.1 Companies such as Dr Reddy’s, Sun Pharma, Cipla, Lupin, Biocon, Zydus, and Aurobindo are preparing generic versions.
0.9.2 Generic drugs offer equivalent therapeutic outcomes at lower prices.
0.9.3 Competition is expected to significantly reduce treatment costs.

1.0 Why 2026 is a turning point

1.0.1 2026 may shift weight loss drugs India from elite usage to wider access.
1.0.2 Obesity treatment is moving towards comprehensive metabolic medicine.
1.0.3 Access will depend on pricing, regulation, and patient acceptance.